Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis

2019 ◽  
Vol 32 (3) ◽  
pp. 156-163
Author(s):  
Heino Stass ◽  
Johannes Nagelschmitz ◽  
Dominik Kappeler ◽  
Knut Sommerer ◽  
Astrid Patzlaff ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Inspiratory Flow ◽  
Dry Powder

Effect of Dry Powder Inhaler Resistance on the Inspiratory Flow Rates and Volumes of Cystic Fibrosis Patients of Six Years and Older

2006 ◽  
Vol 19 (4) ◽  
pp. 456-465 ◽  
Author(s):  
H.A. Tiddens ◽  
D.E. Geller ◽  
P. Challoner ◽  
R.J. Speirs ◽  
K.C. Kesser ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Flow Rates

scholarly journals Inspiratory Flows and Volumes in Subjects with Cystic Fibrosis Using a New Dry Powder Inhaler Device

2014 ◽  
Vol 8 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Mark R. Elkins ◽  
Philip Robinson ◽  
Sandra D. Anderson ◽  
Clare P. Perry ◽  
Evangelia Daviskas ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Inhaler Device ◽  
Device Resistance ◽  
In Series ◽  
Efficient Alternative ◽  
The Mean

Introduction: Drug inhalation via a dry-powder inhaler (DPI) is a convenient, time efficient alternative to nebulizers in the treatment of cystic fibrosis (CF). Efficient drug administration via DPIs depends on the device resistance and adequate (≥ 45L/min) inspiratory flows and volumes generated by individuals. Dry-powder mannitol is delivered using a RS01 breath-actuated device developed by Plastiape, for Pharmaxis. The study aim was to determine in vivo if CF patients’ inspiratory flows and volumes are adequate to use the RS01 DPI device. Materials and Methodology: An open, non-interventional study; enrolled 25 CF subjects, aged ≥ 6 years with FEV1 ≥ 30 to < 90‰ predicted. Inspiratory flows and volumes were measured when subjects inhaled in a controlled manner through the RS01 device in series with a spirometer. Results: The mean inspiratory volume (IV) of CF subjects was 1.83L ± 0.97. Their achieved mean ± SD peak inspiratory flow (PIF) was 75.5 ± 27.2L/min. Twenty-three subjects (92%) achieved PIF of > 45L/min with the inhaler device; eighteen of those subjects (78%) had a baseline FEV1 of > 1L. Conclusion: Use of the RS01 DPI device allowed adequate inspiratory flow and volume for dispersion of dry-powder mannitol in CF patients.

scholarly journals 309 Piloting the use of the cystic fibrosis questionnaire (CFQ) in CF patients changing to dry powder inhaled colistimethate

2007 ◽  
Vol 6 ◽  
pp. S76 ◽  
Author(s):  
S.P. Conway ◽  
J.C. Davies ◽  
C. Etherington ◽  
M.H. Goldman ◽  
E. Howard ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Dry Powder ◽  
Cystic Fibrosis Questionnaire

Development of cefdinir loaded Functionalized carbon Nanotubes dry powder Inhaler for the Treatment of cystic Fibrosis

2021 ◽  
pp. 3839-3845
Author(s):  
Krishnat D. Dhekale ◽  
Ravindra N. Kamble
Keyword(s):  
Carbon Nanotubes ◽  
Cystic Fibrosis ◽  
Drug Loading ◽  
Dry Powder Inhaler ◽  
Dry Powder ◽  
Efficient Treatment ◽  
Multi Walled Carbon Nanotubes ◽  
Stable Product ◽  
Lung Infections ◽  
Walled Carbon Nanotubes

A dry-powder inhaler (DPI) carries medication to lungs as a dry powder, useful against respiratory diseases. The current research was endeavoured to examine the capabilities of Multi-walled carbon nanotubes (MWCNT) as a pulmonary transporter for directing cefdinir to cystic fibrosis (CF). Functionalized MWCNTs were loaded with cefdinir to formulate DPI (F-CEF FMWCNTs DPI) having efficient treatment against lung infections and were evaluated successfully. The outcomes demonstrated that cefdinir loaded FMWCNTs were non-toxic and accomplished 79.73 % entrapment with better flow properties. The optimized formulation had Mass Median Aerodynamic Diameter (MMAD), Fine particle fraction (FPF), and particle size of 3.45±0.09 μm, 58.52±1.06%, 5.25 ± 0.03 μm (CEF FMWCNT DPI) and 4. 29±0.16μm 38.74±1.02%, 7.54 ± 0.02 μm (C-DPI) respectively. The loaded nanotubes showed 72. 63 % release after 15 hours in a controlled manner. The outcome of work recognized a unique, simple, and stable product having improved drug loading and increased dispersibility of carbon nanotubes (CNTs) thus improved bioavailability at a lung infection place with less adverse actions.

scholarly journals Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

2016 ◽  
Vol 4 (8) ◽  
pp. 875-884 ◽  
Author(s):  
Anthony De Soyza ◽  
Timothy Aksamit
Keyword(s):  
Cystic Fibrosis ◽  
Dry Powder

Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults

2004 ◽  
Vol 20 (2) ◽  
pp. 131-137 ◽  
Author(s):  
Edwin A. Bronsky ◽  
Jay Grossman ◽  
Marc J. Henis ◽  
Paul P. Gallo ◽  
Ümit Yegen ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Inspiratory Flow ◽  
Dry Powder ◽  
Flow Rates ◽  
Asthmatic Children

scholarly journals Development and Investigation of Dry Powder Inhalers for Cystic Fibrosis

10.5772/51408 ◽  
2012 ◽  
Author(s):  
Paola Russo ◽  
Antonietta Santoro ◽  
Lucia Prota ◽  
Mariateresa Stigliani ◽  
Rita P.
Keyword(s):  
Cystic Fibrosis ◽  
Dry Powder Inhalers ◽  
Dry Powder
Sign in / Sign up

Export Citation Format

Share Document